
## Mitja Kos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5650913/publications.pdf Version: 2024-02-01



Μιτιλ Κο

#	Article	IF	CITATIONS
1	Initiation of insulin therapy in patients with type 2 diabetes: An observational study. Acta Pharmaceutica, 2022, 72, 147-157.	2.0	1
2	Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors. Acta Diabetologica, 2022, 59, 233-241.	2.5	4
3	The association between medication or alcohol use and the incidence of frailty: a retrospective cohort study. BMC Geriatrics, 2021, 21, 25.	2.7	10
4	Improved adherence with Medicines Use Review service in Slovenia: a randomized controlled trial. BMC Health Services Research, 2021, 21, 266.	2.2	3
5	Prevalence and incidence of frailty among community-dwelling older adults in Slovenia. Zdravstveno Varstvo, 2021, 60, 190-198.	0.9	Ο
6	Uptake of new antidiabetic medicines in 11 European countries. BMC Endocrine Disorders, 2021, 21, 127.	2.2	11
7	Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study. BMJ Open, 2021, 11, e051549.	1.9	10
8	Regulatory and clinical perspective on patient access to antidiabetic medicines in Slovenia. Srpski Arhiv Za Celokupno Lekarstvo, 2021, 149, 461-466.	0.2	0
9	A survey to assess the availability, implementation rate and remuneration of pharmacist-led cognitive services throughout Europe. Research in Social and Administrative Pharmacy, 2020, 16, 41-47.	3.0	22
10	Inhalation technique and asthma outcomes with different corticosteroid-containing inhaler devices. Journal of Asthma, 2020, 57, 654-662.	1.7	12
11	Community pharmacist-led medication review procedures across Europe: Characterization, implementation and remuneration. Research in Social and Administrative Pharmacy, 2020, 16, 1057-1066.	3.0	34
12	The impact of reference pricing on healthcare outcomes in patients with arterial hypertension. Health Policy and Technology, 2020, 9, 356-361.	2.5	1
13	Development, validation and performance of a newly designed tool to evaluate functional medication literacy in Slovenia. International Journal of Clinical Pharmacy, 2020, 42, 1490-1498.	2.1	7
14	Anticholinergic Burden in Children, Adults and Older Adults in Slovenia: A Nationwide Database Study. Scientific Reports, 2020, 10, 9337.	3.3	18
15	Pharmacy-supported interventions at transitions of care: an umbrella review. International Journal of Clinical Pharmacy, 2019, 41, 831-852.	2.1	8
16	Medicine Prices in European Countries. , 2019, , 11-29.		2
17	Review of studies reporting actual prices for medicines. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 159-179.	1.4	14
18	Patient Access to Medicines for Rare Diseases in European Countries. Value in Health, 2018, 21, 553-560.	0.3	48

Μιτја Kos

#	Article	IF	CITATIONS
19	Introduction of therapeutic reference pricing in Slovenia and its economic consequences. European Journal of Health Economics, 2018, 19, 571-584.	2.8	5
20	Clinically relevant potential drug–drug interactions among outpatients: A nationwide database study. Research in Social and Administrative Pharmacy, 2018, 14, 572-580.	3.0	34
21	Community pharmacists' perspectives on implementation of Medicines Use Review in Slovenia. International Journal of Clinical Pharmacy, 2018, 40, 1180-1188.	2.1	6
22	Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion. BMC Health Services Research, 2018, 18, 496.	2.2	6
23	PCNE definition of medication review: reaching agreement. International Journal of Clinical Pharmacy, 2018, 40, 1199-1208.	2.1	137
24	Influence of generic reference pricing on medicine cost in Slovenia: a retrospective study. Croatian Medical Journal, 2018, 59, 79-89.	0.7	6
25	Medication adherence and health-related quality of life among patients with chronic obstructive pulmonary disease. Acta Pharmaceutica, 2018, 68, 117-125.	2.0	8
26	The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin. American Journal of Cardiovascular Drugs, 2017, 17, 399-408.	2.2	2
27	Influence of novel oral anticoagulants on anticoagulation care management. Acta Pharmaceutica, 2017, 67, 397-406.	2.0	1
28	Development and performance of the external reference pricing system in Slovenia from 2007 to 2012. Health Policy and Technology, 2017, 6, 348-357.	2.5	0
29	Curriculum Mapping of the Master's Program in Pharmacy in Slovenia with the PHAR-QA Competency Framework. Pharmacy (Basel, Switzerland), 2017, 5, 24.	1.6	4
30	Medication and supplement use in older people with and without intellectual disability: An observational, cross-sectional study. PLoS ONE, 2017, 12, e0184390.	2.5	31
31	Criterion validity of 8-item Morisky Medication Adherence Scale in patients with asthma. PLoS ONE, 2017, 12, e0187835.	2.5	38
32	Type 2 diabetes: cost-effectiveness of medication adherence and lifestyle interventions. Patient Preference and Adherence, 2016, Volume 10, 2039-2049.	1.8	7
33	Development and validation of the Slovenian drug-related problem classification system based on the PCNE classification V 6.2. International Journal of Clinical Pharmacy, 2016, 38, 950-959.	2.1	7
34	Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. Journal of Dairy Science, 2016, 99, 5008-5021.	3.4	59
35	Patients' knowledge and attitude towards therapeutic reference pricing system in Slovenia. International Journal of Clinical Pharmacy, 2016, 38, 1301-1310.	2.1	5
36	The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement. Radiology and Oncology, 2015, 49, 200-208.	1.7	3

Μιτја Kos

#	Article	IF	CITATIONS
37	Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control. Pharmacoeconomics, 2015, 33, 395-408.	3.3	46
38	Contribution of Slovenian community pharmacist counseling to patients' knowledge about their prescription medicines: a cross-sectional study. Croatian Medical Journal, 2015, 56, 41-49.	0.7	17
39	Sedative Load and Frailty Among Community-Dwelling Population Aged ≥65 Years. Journal of the American Medical Directors Association, 2015, 16, 282-289.	2.5	32
40	Reply to response to Limitations of the study "Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults― Vaccine, 2015, 33, 17.	3.8	0
41	Economic burden of cardiovascular diseases in Serbia. Vojnosanitetski Pregled, 2014, 71, 137-143.	0.2	19
42	Concurrent Use of Drugs and Supplements in a Community-Dwelling Population Aged 50ÂYears or More: Potential Benefits and Risks. Drugs and Aging, 2014, 31, 527-540.	2.7	15
43	Limitations of the study "Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults― Vaccine, 2013, 31, 2601.	3.8	2
44	Food supplement use in the community dwelling population aged 50 and over in the Republic of Ireland. Complementary Therapies in Medicine, 2013, 21, 333-341.	2.7	15
45	Burden of Type 2 Diabetes from the Healthcare Payer Perspective in Slovenia / Breme Sladkorne Bolezni Tipa 2 S StaliÅ¡Äa PlaÄnika Zdravstvenega Varstva V Sloveniji. Zdravstveno Varstvo, 2013, 52, 162-180.	0.9	7
46	Use of Simulated Patients to Evaluate Combined Oral Contraceptive Dispensing Practices of Community Pharmacists. PLoS ONE, 2013, 8, e79875.	2.5	24
47	Pharmacy network and access to medicines in selected eastern European countries: comparative analysis. Croatian Medical Journal, 2012, 53, 53-59.	0.7	4
48	The Cost-Effectiveness of Hypertension Pharmacotherapy in Serbia: A Markov Model. Biotechnology and Biotechnological Equipment, 2012, 26, 3066-3072.	1.3	4
49	Using the Simulated Patient Methodology to Assess Paracetamol-Related Counselling for Headache. PLoS ONE, 2012, 7, e52510.	2.5	44
50	Slovenian pharmacy performance: a patient-centred approach to patient satisfaction survey content development. International Journal of Clinical Pharmacy, 2011, 33, 985-996.	2.1	13
51	Analysis of inappropriate medication prescribing in Slovenian elderly patients based on the Beers and Laroche criteria. Zdravstveno Varstvo, 2011, 50, .	0.9	1
52	Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. European Journal of Public Health, 2010, 20, 415-421.	0.3	15
53	A Multimarker Approach for the Prediction of Coronary Artery Disease: Cost-Effectiveness Analysis. Value in Health, 2010, 13, 770-777.	0.3	6
54	Development and Initial Validation of a Patient Satisfaction With Pharmacy Performance Questionnaire (PSPP-Q). Evaluation and the Health Professions, 2010, 33, 197-215.	1.9	22

Μιτја Kos

#	Article	IF	CITATIONS
55	Market uptake of biologic and small-molecule—Targeted oncology drugs in Europe. Clinical Therapeutics, 2009, 31, 2940-2952.	2.5	5
56	Body shape, body size and cigarette smoking relationships. International Journal of Public Health, 2009, 54, 35-39.	2.6	9
57	Response to the comments on â€ <sup>-</sup> Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia' by Steve S. Koh and Jonathan M. Meyer. International Journal of Clinical Practice, 2008, 62, 1119-1120.	1.7	Ο
58	Cost–effectiveness of <i>UGT1A1</i> genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics, 2008, 9, 539-549.	1.3	43
59	Accessibility to targeted oncology drugs in Slovenia and selected European countries. European Journal of Cancer, 2008, 44, 408-418.	2.8	10
60	Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. International Journal of Clinical Practice, 2007, 61, 1979-1988.	1.7	29
61	Physicians' awareness of nonapproved drug indications in Slovenia. American Journal of Health-System Pharmacy, 2006, 63, 2184-2186.	1.0	1
62	Satisfaction with Pharmacotherapy for Approved and Off-Label Indications—A Delphi Study. Annals of Pharmacotherapy, 2005, 39, 649-654.	1.9	11
63	Systemic conditions for performance of pharmacoepidemiologic studies in Slovenia. Pharmacoepidemiology and Drug Safety, 2001, 10, 675.	1.9	2